Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Ann Arbor Staging (Histiocytic Sarcoma)

Due to the rarity of Histiocytic Sarcoma and its lymphoid-like spread pattern, the Ann Arbor staging system (originally for lymphoma) is commonly used to describe the extent of disease and guide treatment (Localized vs.

Evidence-based context for fast calculator use

Purpose:
Ann Arbor staging classifies histiocytic sarcoma extent by nodal and extranodal involvement to guide treatment between localized and systemic.
Population:
patients with suspected or confirmed histiocytic or hyperinflammatory disease matching the original criteria
Factors:
Nodal / Extranodal Involvement, Systemic Symptoms?
Reference:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Histiocytic Neoplasms.
HomeAnn Arbor Staging (Histiocytic Sarcoma)
Pin your most used calculators here by clicking the star in the dropdown.

Ann Arbor Staging (Histiocytic Sarcoma)

Clinical Context & Background

Due to the rarity of Histiocytic Sarcoma and its lymphoid-like spread pattern, the Ann Arbor staging system (originally for lymphoma) is commonly used to describe the extent of disease and guide treatment (Localized vs. Disseminated).
Primary Source EvidenceNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Histiocytic Neoplasms.
Formula Logic
Stage I-IV based on nodal/extranodal sites and diaphragm.

Reference Data

StageDescription
Stage ISingle node region or single extranodal site (IE)
Stage IITwo or more node regions same side of diaphragm
Stage IIINodal regions on both sides of diaphragm
Stage IVDisseminated extranodal involvement (Liver, Marrow, Lung)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use Ann Arbor Staging (Histiocytic Sarcoma) when ann Arbor staging classifies histiocytic sarcoma extent by nodal and extranodal involvement to guide treatment between localized and systemic.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Stage I through Stage IV.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm pathology, organ involvement, infectious and malignant mimics, laboratory trends, and urgent specialist input.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Classification and hyperinflammation scores do not replace diagnostic criteria or emergency treatment assessment.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with suspected or confirmed histiocytic or hyperinflammatory disease matching the original criteria

How to apply this result

For a representative case, verify Nodal / Extranodal Involvement, Systemic Symptoms?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Related Tools

HLH-2004 Diagnostic Criteria Calculator — Hemophagocytic LymphohistiocytosisHScore for HLHLCH Risk Organ Classification

Frequently Asked Questions

When should Ann Arbor Staging (Histiocytic Sarcoma) be used?

Use it for patients with suspected or confirmed histiocytic or hyperinflammatory disease matching the original criteria when all required inputs and the intended clinical setting are confirmed.

Can Ann Arbor Staging (Histiocytic Sarcoma) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.